Group One Trading
ADMA icon

Group One Trading’s ADMA Biologics ADMA Stock Holding History

Group One Trading’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$386K Sell
46,100
-9,900
-18% -$90.2K ﹤0.01% 3741
2026
Q1 		$505K Buy
56,000
+15,600
+39% +$246K ﹤0.01% 3341
2025
Q4 		$737K Sell
40,400
-82,700
-67% -$1.39M ﹤0.01% 3169
2025
Q3 		$1.8M Buy
123,100
+66,800
+119% +$1.15M ﹤0.01% 2422
2025
Q2 		$1.03M Buy
56,300
+11,500
+26% +$235K ﹤0.01% 2737
2025
Q1 		$889K Buy
44,800
+5,800
+15% +$100K ﹤0.01% 2558
2024
Q4 		$669K Buy
39,000
+22,900
+142% +$431K ﹤0.01% 2933
2024
Q3 		$322K Sell
16,100
-1,300
-7% -$20.2K ﹤0.01% 3206
2024
Q2 		$195K Buy
17,400
+16,900
+3,380% +$142K ﹤0.01% 3410
2024
Q1 		$3.3K Buy
+500
New +$2.73K ﹤0.01% 6340
2023
Q4 		– Sell
-11,500
Closed -$41.2K – 7293
2023
Q3 		$41.2K Sell
11,500
-44,400
-79% -$171K ﹤0.01% 5284
2023
Q2 		$206K Buy
55,900
+9,600
+21% +$35.6K ﹤0.01% 3896
2023
Q1 		$153K Sell
46,300
-33,700
-42% -$116K ﹤0.01% 3905
2022
Q4 		$310K Sell
80,000
-30,800
-28% -$95K ﹤0.01% 3466
2022
Q3 		$269K Buy
110,800
+47,500
+75% +$114K ﹤0.01% 3854
2022
Q2 		$125K Buy
63,300
+46,100
+268% +$90.7K ﹤0.01% 4768
2022
Q1 		$31K Sell
17,200
-773,600
-98% -$1.21M ﹤0.01% 6447
2021
Q4 		$1.11M Buy
790,800
+52,200
+7% +$68.6K ﹤0.01% 3246
2021
Q3 		$835K Sell
738,600
-219,900
-23% -$308K ﹤0.01% 3608
2021
Q2 		$1.53M Buy
958,500
+47,700
+5% +$83.9K ﹤0.01% 2919
2021
Q1 		$1.6M Buy
910,800
+418,800
+85% +$959K ﹤0.01% 2706
2020
Q4 		$959K Buy
492,000
+104,500
+27% +$220K ﹤0.01% 2673
2020
Q3 		$926K Buy
387,500
+158,100
+69% +$434K ﹤0.01% 2268
2020
Q2 		$672K Buy
229,400
+7,000
+3% +$20.1K ﹤0.01% 2377
2020
Q1 		$641K Buy
+222,400
New +$769K 0.01% 1867
2019
Q4 		– Sell
-2,100
Closed -$9K – 5050
2019
Q3 		$9K Sell
2,100
-900
-30% -$3.76K ﹤0.01% 4614
2019
Q2 		$12K Buy
+3,000
New +$13.2K ﹤0.01% 4352

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Group One Trading's ADMA Position: Q2 2026 in Review

Group One Trading reduced its ADMA Biologics (ADMA) stake by 92% in Q2 2026, selling an estimated $586K and leaving 5,911 shares worth $49.5K. The position accounts for ﹤0.01% of the portfolio, ranked #5413.

Group One Trading first reported a position in ADMA in Q3 2018 and has held it in 18 quarters since. The position peaked at $3.49M in Q4 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Group One Trading held 5,911 shares of ADMA Biologics worth $49.5K as of Q2 2026.
  • Group One Trading sold 64,272 ADMA Biologics shares in Q2 2026, an estimated $586K.
  • ADMA Biologics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #5413 holding.
  • Group One Trading first reported a position in ADMA Biologics in Q3 2018 and has held it in 18 quarters since.
  • Group One Trading's ADMA Biologics position peaked at $3.49M in Q4 2025.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.